Nuvectis Pharma, Inc. Professional Fees
Nuvectis Pharma, Inc. (NVCT) reported Professional Fees of $5.25 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ProfessionalFees · last filed 2026-02-11
- Nuvectis Pharma, Inc. professional fees for fiscal 2025 was $5.25M, a 51.73% increase from fiscal 2024.
- Nuvectis Pharma, Inc. professional fees for fiscal 2024 was $3.46M, a 0.06% increase from fiscal 2023.
- Nuvectis Pharma, Inc. professional fees for fiscal 2023 was $3.46M, a 45.32% increase from fiscal 2022.
- Nuvectis Pharma, Inc. professional fees for fiscal 2022 was $2.38M, a 7.50% decline from fiscal 2021.
| Period end | Professional Fees 12 month |
|---|---|
| 2025-12-31 | $5.25M 10-K · filed 2026-02-11 |
| 2024-12-31 | $3.46M 10-K · filed 2026-02-11 |
| 2023-12-31 | $3.46M 10-K · filed 2025-02-25 |
| 2022-12-31 | $2.38M 10-K · filed 2024-03-05 |
| 2021-12-31 | $2.57M 10-K · filed 2023-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |